Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

82.77USD
25 May 2018
Change (% chg)

$0.06 (+0.07%)
Prev Close
$82.71
Open
$82.79
Day's High
$83.47
Day's Low
$82.60
Volume
626,903
Avg. Vol
1,346,384
52-wk High
$89.07
52-wk Low
$73.70

Chart for

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.27
Market Cap(Mil.): $89,841.08
Shares Outstanding(Mil.): 1,085.43
Dividend: 0.56
Yield (%): 2.72

Financials

  LLY.N Industry Sector
P/E (TTM): 28.68 29.19 33.30
EPS (TTM): 2.89 -- --
ROI: 10.15 13.53 13.04
ROE: 21.28 15.25 14.90

REFILE-UPDATE 5-Zoetis to buy veterinary diagnostics firm Abaxis for $1.9 bln

* Zoetis says diagnostics should grow faster than animal health

May 16 2018

Lilly to buy cancer drug developer AurKa Pharma

Eli Lilly and Co will buy AurKa Pharma Inc in a deal potentially worth up to $575 million, the U.S. drugmaker said on Monday, seeking access to the privately-held firm's experimental cancer treatment for solid tumors.

May 14 2018

Eli Lilly to buy cancer drug developer AurKa Pharma

May 14 Drugmaker Eli Lilly and Co said on Monday it would buy AurKa Pharma Inc to get access to the privately-held company's experimental cancer treatment for solid tumors.

May 14 2018

BRIEF-HBM Healthcare Investments: Eli Lilly Announces Tender Offer For HBM-Portfolio Company

* ELI LILLY ANNOUNCES TENDER OFFER FOR HBM-PORTFOLIO COMPANY ARMO BIOSCIENCES FOR USD 1.6 BILLION

May 11 2018

BRIEF-Armo Biosciences - Upon Termination Of Merger Under Specified Circumstances Co May Be Required To Pay Eli Lilly Fee Of $63.4 Mln

* ARMO BIOSCIENCES - UPON TERMINATION OF MERGER UNDER SPECIFIED CIRCUMSTANCES CO MAY BE REQUIRED TO PAY ELI LILLY TERMINATION FEE OF $63.4 MILLION Source: (https://bit.ly/2I7j4vd) Further company coverage:

May 10 2018

Lilly to buy Armo Biosciences for $1.6 billion to bolster cancer pipeline

Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to expand its portfolio of drugs that helps body's immune system fight cancer as the U.S. drugmaker chases rivals in a lucrative market.

May 10 2018

Lilly to buy Armo Biosciences for $1.6 bln

May 10 Drugmaker Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to get access to the drug developer's experimental cancer treatment.

May 10 2018

BRIEF-Elanco Animal Health Announces Addition Of General Counsel

* ELANCO ANIMAL HEALTH - NAMED MICHAEL-BRYANT HICKS AS GENERAL COUNSEL

May 10 2018

BRIEF-Eli Lilly Shareholders Elect The 5 Nominees For Director To 3-Yr Terms Ending In 2021

* ELI LILLY SAYS THE 5 NOMINEES FOR DIRECTOR WERE ELECTED TO SERVE 3-YEAR TERMS ENDING IN 2021 BY VOTING SHAREHOLDERS AT 2018 ANNUAL MEETING - SEC FILING Source text: (http://bit.ly/2jGhwcQ) Further company coverage:

May 08 2018

UPDATE 2-Novo Nordisk upbeat on new diabetes drug as profit tops forecast

* U.S. legislation puts pressure on 2019 sales (Adds CEO quotes, share price)

May 02 2018

Competitors

Earnings vs. Estimates